AI for medical publishing and medical communications
The hours in medical publishing sit in four places: MLR review, systematic literature review, regulatory writing, and the tracking spreadsheets that hold publication plans together.
Medical publishing is one of the most document-dense, compliance-bound and quietly spreadsheet-run industries there is, which makes it close to ideal for AI, and unusually dangerous to automate carelessly. This page covers where the hours actually are, the one rule that closes the obvious shortcut, and what that means for buying versus building.
Last updated: 6 August 2026
The hours in medical publishing sit in four places: MLR review, systematic literature review, regulatory writing, and the tracking spreadsheets that hold publication plans together. Industry figures are substantial: Veeva reports up to 75% MLR cycle-time reduction with AI support, and Merck cut first-draft CSR authoring from 180 to 80 hours. But the obvious route is closed: major publishers explicitly warn against putting unpublished manuscripts or patient data into general LLMs, and ICMJE bars AI from authorship while requiring disclosure. That constraint, not the technology, decides your architecture.
The one constraint that shapes everything else
Before any tool discussion, this: the major medical publishers explicitly warn against uploading unpublished manuscripts or patient data into general-purpose LLMs. Wiley, Wolters Kluwer (Lippincott) and Elsevier all carry that warning. Science, Springer Nature and The Lancet go further on imagery, generally prohibiting AI-generated or AI-altered figures to prevent data manipulation.
Separately, ICMJE has required since May 2023 that authors disclose the use of AI-assisted technologies in manuscript preparation, and forbids listing AI as an author or co-author. GPP 2022 extends the same transparency logic across manuscripts, abstracts, posters, congress presentations, plain language summaries and preprints.
The practical consequence is blunt. In most industries, "just use ChatGPT for a while and see" is sound, low-cost advice. We give it constantly. In medical publishing it is not available. The moment unpublished data leaves your control, you have a problem that no efficiency gain repays. That single fact is why this sector's build-versus-buy answer differs from every other sector's, and why so much generic AI advice is actively wrong here.
The four places the time actually goes
Industry figures below are third-party and cited as such, not Crux results. They are useful as orientation for what is achievable, not as a promise.
| Process | The manual reality | Reported with AI support |
|---|---|---|
| MLR review (medical, legal, regulatory) | Cross-functional sign-off on every promotional and scientific asset; cycles routinely run weeks | Veeva reports up to 75% cycle-time reduction; Falcon MLR targets 70% less manual MLR labour over five years |
| Systematic literature review | Title/abstract screening plus full-text extraction: 4–6 weeks of subject-matter-expert time | Screening pool cut by more than half within days; extraction validated in days rather than weeks |
| Regulatory writing (CSR) | First-draft clinical study report authoring measured in weeks | Merck: 2–3 weeks → 3–4 days, first draft 180 → 80 hours, errors halved. QInscribe reports ~90% faster draft generation |
| Publication planning & tracking | Spreadsheets: congress deadlines, author disclosures, reference checks, version state | Rarely automated at all, and roughly 88% of spreadsheets contain errors |
The publication tracker nobody wants to talk about
Every MedComms team and medical affairs group we have looked at runs at least one enormous spreadsheet: the publication plan, the MLR tracker, the congress calendar, the author-disclosure log. It is usually the single most load-bearing object in the department.
It is also, quite genuinely, an achievement. Somebody built it because nobody gave them a system, and it has outlived reorganisations, platform migrations and its own author. The problem is not that it is primitive. The problem is that roughly 88% of spreadsheets contain errors, and in this industry an error is not a rounding difference: it is a missed disclosure, a wrong version submitted, or a congress deadline discovered late.
This is usually the least expensive, lowest-risk place to start, precisely because it touches process metadata rather than unpublished scientific content. No manuscript leaves the building.
What actually binds you
Four regimes overlap here, and they are frequently conflated:
- Publisher and journal policy: the LLM-upload warnings and image prohibitions above. Contractual and reputational, not statutory, and the fastest to bite.
- ICMJE and GPP 2022: disclosure of AI assistance; AI cannot be an author; medical-writing support must be declared.
- EU AI Act: most publishing work makes you a deployer of limited-risk AI. Article 4 AI-literacy has applied since February 2025; transparency obligations from August 2026. The heavy Annex III regime was postponed to December 2027 and rarely applies to publishing itself. See our AI Act guide.
- GxP and data integrity: where work touches regulatory submissions, ALCOA+ expectations and validated-system rules apply. An AI step inside a regulated workflow needs the same audit trail as any other step.
What this means for how the system is built
Given the upload constraint, three design decisions follow, and they are not optional:
- The content stays where it already is. Processing happens inside your tenancy or on infrastructure you control, not by pasting into a consumer tool. This is the whole reason self-hostable stacks matter more here than elsewhere; see our platform comparison.
- Every AI step is logged. What was suggested, what the human accepted, who signed off. You will need that for disclosure and, in regulated work, for audit.
- The human is the author, structurally. Not as a policy sentence but as a workflow that cannot proceed without a named sign-off, the pattern that produced 100% clinician sign-off in our clinical-NLP work.
The order that works
Ranked by payback and by how little unpublished content is exposed.
| # | Start with | Why first |
|---|---|---|
| 1 | Publication-plan and MLR tracking | Process metadata only: no manuscripts leave. Fast, low risk, immediately visible |
| 2 | Reference and consistency checking | Mechanical, high-volume, and where late-stage errors are most expensive |
| 3 | SLR screening support | Biggest single block of SME time; human validates every inclusion |
| 4 | Drafting support inside your own tenancy | Highest value, highest constraint: only once 1–3 have proven the guardrails |
What we will tell you before you spend anything
Crux Digits builds AI systems; we are not a medical writing agency and not a regulatory consultancy. Three things we will say early rather than late.
First, if your bottleneck is scientific judgement rather than document handling, AI will not help much and we will say so. The two-number test in our AI for business guide applies here as everywhere.
Second, several established tools already cover parts of this well. If DistillerSR or a Veeva capability you already licence solves your problem, buy that, not a build. Our tools comparison exists to help you check.
Third, we publish our prices: an audit at €2,500, a Production-ready MVP on your own workflow at €20,000, production from €50,000. You will know the cost before each step and you can stop after any of them.
Compare further
Frequently asked questions
Can we use ChatGPT for medical writing?
How much time does AI actually save in medical publishing?
Does the EU AI Act apply to medical publishing?
Can AI be listed as an author on a paper?
Should we build or buy AI for medical publishing?
Where should a MedComms team start?
Sitting on a publication tracker nobody trusts?
Twenty minutes, no deck. We will tell you which of the four processes is worth automating first, and if the answer is none, we will say that.
Book a free consultation →